Elanco Animal Health (ELAN) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 68.4% versus a gain of 9.3%. Over five years, JAZZ leads with a +64.3% price change compared with -31.3% for ELAN. Jazz Pharmaceuticals is the larger company by market cap ($14.44 billion vs $11.26 billion), about 1.3 times the size, while Elanco Animal Health is growing revenue faster (+6.2% vs +4.9%).
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.6x vs 17.5x for Elanco Animal Health). Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAN | JAZZ |
|---|---|---|
| Share price | $22.54 | $222.45 |
| Market cap | $11.26B | $14.44B |
| 1-day change | +0.81% | -3.78% |
| YTD return | -1.19% | +35.99% |
| 1-year return | +9.34% | +68.36% |
| 5-year return | -31.28% | +64.31% |
| P/E ratio (TTM) | — | 15.25 |
| Forward P/E | 17.54 | 8.58 |
| EPS (TTM) | $-0.41 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.71B | $4.27B |
| Revenue growth (YoY) | +6.22% | +4.88% |
| Net income (latest FY) | $-232.00M | $-356.15M |
| Gross margin | 54.99% | — |
| Operating margin | — | -10.08% |
| Net margin | -4.92% | -8.35% |
| 52-week high | $27.98 | $266.38 |
| 52-week low | $19.40 | $128.80 |
| Distance from 52-week high | -19.44% | -16.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.53% | +32.39% |
| Average volume | 6.18M | 850.55K |
| Shares outstanding | 499.45M | 64.91M |
| Employees | 9,400 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed ELAN by 59.0 percentage points over the past year.
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
ELAN vs JAZZ FAQ
Which is bigger, Elanco Animal Health or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.44B compared with $11.26B for Elanco Animal Health (ELAN).
Which stock has performed better over the past year, ELAN or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +9.34% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are Elanco Animal Health and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.